Search Results - Lora Hamuro

  • Showing 1 - 1 results of 1
Refine Results
  1. 1
    A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1‐3 Rearrangements

    A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harbo... by Shengnan Du, Zheyi Hu, Jun Shen, Lora Hamuro, Justine Lam, Ming Lu, Li Zhu, Amit Roy, Anna Kondic

    Published 2025-07-01

    ABSTRACT Repotrectinib is approved in the US for treating ROS1‐positive non‐small cell lung cancer (NSCLC) and solid tumors harboring an NTRK gene fusion. A Population Pharmacokinetic (PopPK) model for repotrectinib was developed using data from 620 adults (118 healthy volunteers and 502 patients) a...

    Full description

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: